Introduction
============

Atopic dermatitis is a chronic, inflammatory skin condition that affects 10% to 20% of children and 1% to 3% of adults in the US ([@b10-ppa-2-387]). Symptoms include erythema, scaling and pruritus in affected areas, and often result in sleeplessness, psychological stress, poor self-esteem, anxiety, and poor school or work preformance. The cost of atopic dermatitis is estimated to be US\$0.9 to 3.8 billion every year, with direct medical costs and out-of-pocket expenses averaging US\$609/patient/year ([@b14-ppa-2-387]). Topical steroids have been the mainstay of treatment for atopic dermatitis in both children and adults for over 50 years. Recent advances in vehicle technologies have resulted in the development of novel gel and foam formations of several topical steroids, and have improved patient tolerability and compliance. Although the efficacy of topical steroids is well-established, use may be limited by potential side effects and many patients with more severe disease require additional therapy. Topical calcineurin inhibitors have proven to be safe and effective in the treatment of atopic dermatitis, providing an additional therapeutic option for patients with this disease. In addition to advances in topical treatments for atopic dermatitis, systemic immunomodulators are becoming more prevalent in the treatment of severe, refractory disease. Cyclosporine, methotrexate, azathioprine, mycophenolate mofetil, and interferon gamma (IFN-γ) have been used in the management of severe atopic dermatitis. The aim of this review is to present the current and emerging trends in the treatment of atopic dermatitis.

Topical steroids: new formulations
==================================

The use of topical corticosteroids in dermatology began only 50 years ago, yet these medications are now considered first-line therapy for adult and pediatric patients with atopic dermatitis ([@b20-ppa-2-387]). Topical steroids have immunosuppressive, anti-inflammatory, antiproliferative, and vasoconstrictive effects that have been shown to reduce itching, improve the appearance of skin, and improve quality of life. Until recently, only creams, ointments, and lotions were available, but now new hydrogel and foam formulations have been developed. These advances in vehicle technology provide additional therapeutic options for patients with atopic dermatitis, and may enhance patient compliance and acceptability. Side effects associated with topical steroid use include cutaneous atrophy, striae, telangiectasias, contact dermatitis, Cushing's syndrome, growth retardation, and suppression of the hypothalmamic-pituitary-adrenal axis ([@b2-ppa-2-387]; [@b22-ppa-2-387]). These potential side effects can be concerning to both patients and physicians and may result in decreased prescribing and compliance.

Topical calcineurin inhibitors
==============================

Topical tacrolimus and pimecrolimus are calcineurin inhibitors that were developed for the treatment of atopic dermatitis. Inhibition of calcineurin results in decreased transcription of IL-2, with resulting decreases in T-cell activation and cytokine production. Topical calcineurin inhibitors (TCIs) cause depletion of inflammatory dendritic cells in atopic dermatitis lesions, decrease histamine release from mast cells and basophils, and prevent the T-cell proliferation that results from *Staphylococcus aureus* super-antigens ([@b22-ppa-2-387]). One of the greatest advantages of these newer medications is the absence of many of the side effects associated with topical corticosteroids, including cutaneous atrophy, striae, telangiectasias, and hypothalamic-pituitary-adrenal (HPA) axis suppression. TCIs have been shown to be safe and effective in numerous clinical trials, and provide additional therapeutic options for the treatment of atopic dermatitis.

Currently, Food and Drug Administration (FDA) guidelines for the use of TCIs recommend that these medications should not be used in children younger than 2 years of age or in immunocompromised patients. TCIs are indicated as short-term or non-continuous, long-term treatment of atopic dermatitis in patients who have not responded to other topical treatments, or in whom these other treatments are not recommended. Pimecrolimus 1% cream is FDA-approved for the treatment of mild to moderate atopic dermatitis in patients 2 years of age or older. Tacrolimus 0.1% ointment is approved for the treatment of moderate to severe atopic dermatitis in patients 16 years of age or older, and tacrolimus 0.03% ointment is approved for use in patients 2 years of age or older ([@b16-ppa-2-387]; [@b14-ppa-2-387]; [@b22-ppa-2-387]).

A comparative study of tacrolimus 0.1% ointment demonstrated efficacy comparable to the midpotency corticosteriod hydrocortisone butyrate 0.1% ([@b17-ppa-2-387]). A study of pediatric patients showed superior efficacy of 0.03% and 0.1% tacrolimus ointment when compared to hydrocortisone acetate 1% ([@b18-ppa-2-387]).

Multiple clinical trials evaluating pimecrolimus cream 1% for the treatment of atopic dermatitis demonstrated superior efficacy when compared with vehicle creams, as well as reduced frequency of flares, and reduced need for topical corticosteroids ([@b8-ppa-2-387]).

Finally, 3 multi-center, randomized, investigator-blinded studies involving a total of 1065 adult and pediatric patients with mild to very severe atopic dermatitis compared the efficacy and safety of tacrolimus ointment to pimecrolimus cream. Tacrolimus ointment was found to be significantly more effective than pimecrolimus cream in adults and children with moderate to very severe disease. In pediatric patients with mild disease, the improvements in the tacrolimus group were significantly greater at week one and trended towards continued advantage at the end of the study. Patients treated with tacrolimus also showed faster onset of action, and greater improvement in itch scores, percentage of body surface area affected and Investigator Global AD Assessment scores. There was no significantly difference in adverse events between the two treatment groups. The number of local application site reactions experienced on day one was greater in adults treated with tacrolimus, but the incidence on all subsequent days was equal in both groups. More patients in the pimecrolimus group withdrew from the studies due to lack of efficacy ([@b16-ppa-2-387]).

The most common adverse effects associated with the use of TCIs are local application site reactions. These include skin burning, stinging and pruritus. Unlike topical corticosteroids, TCIs have not been found to cause HPA axis suppression, skin atrophy, striae, or telangiectasias, and are safe to use even on the thin skin of the face and neck.

A black box warning and patient medication guide were added to TCI labels in January 2006 due to safety concerns raised by the FDA ([@b8-ppa-2-387]). These concerns were related to the immunosuppression and increased incidence of lymphoproliferative disease associated with systemically-administered calcineurin inhibitors in transplant patients, and to studies in animal models involving high doses of orally-administered drug. Although rare cases of lymphoma and skin malignancies have been reported in post-marketing surveillance studies, no causal relationship has been established between these cases and the use of TCIs, and the reported lymphoma cases were no greater than the expected rate in the general population ([@b8-ppa-2-387]; [@b14-ppa-2-387]). Numerous pharmacokinetic studies have shown that the administration of topical pimecrolimus or tacrolimus results in negligible amounts of drug absorption into the systemic circulation ([@b14-ppa-2-387]). After careful review of safety data, The American Academy of Dermatology, the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology released statements that data did not suggest increased malignancy risk with the use of TCIs and that they did not support the black-box warning ([@b8-ppa-2-387]; [@b14-ppa-2-387]).

Cyclosporine
============

Cyclosporine A (CsA) was isolated from the soil fungus *Tolypocladium inflatum* in 1970. This medication is a potent immunosuppressant that inhibits cell-mediated immunity, and was approved in the US in 1983 for the prophylaxis of organ transplant rejection ([@b9-ppa-2-387]; [@b22-ppa-2-387]). Cyclosporine is now approved in the US for the treatment of psoriasis, and is licensed in Europe for the short-term treatment of severe atopic dermatitis in adults ([@b4-ppa-2-387]). In the US, cyclosporine is used off-label for the short-term treatment of severe atopic dermatitis in both children and adults. Cylosponine shares a common mechanism of action with the TCIs. This medication inhibits calcineurnin, resulting in decreased production of IL-2 and other inflammatory cytokines and preventing the activation and proliferation of T cells. Due to its high molecular weight, cyclosporine is not effective topically and must be administered orally.

A large meta-analysis of 15 European studies evaluated the use of cyclosporine in the treatment of severe atopic dermatitis in over 600 children and adults. Treatment duration ranged from 6 weeks to 12 months. All studies showed a mean decrease in the severity of atopic dermatitis. Twelve of the studies were pooled, and the results demonstrated dose-related improvements in atopic dermatitis with cyclosporine treatment. Two weeks into treatment, patients receiving low-dose therapy (≤3 mg/kg) showed a mean decrease in disease severity of 22%, and patients on high dose therapy (≥4 mg/kg) showed a 40% decrease in disease severity. After 6 to 8 weeks, relative effectiveness was 55%. Three of the included studies assessed health-related quality of life and all three found significantly improvements with cyclosporine treatment. Adverse events included reversible increases in creatinine, hypertension, infections, gastrointestinal symptoms, headache and paresthesias ([@b19-ppa-2-387]).

A retrospective review of 15 Chinese patients ages 1 to 58 years with severe atopic dermatitis treated with oral cyclosporine demonstrated rapid improvement in disease severity 2 weeks after initiating treatment. At the end of treatment, 73% of the patients showed improvement in their disease; however, relapses were noted in all patients within 3 months of cessation of cyclosporine. Worsening blood pressure occurred in 1 patient who had borderline hypertension prior to cyclosporine treatment; return to baseline occurred after cessation of cyclosporine ([@b9-ppa-2-387]).

A retrospective study of 73 adult patients from the Netherlands evaluated the long-term safety and efficacy of cyclosporine A for the treatment of atopic dermatitis. Patients received treatment for an average of 1.3 years, with doses ranging from 2.5 to 5 mg/kg/day. Successful treatment (50%--100% improvement) was achieved in 77%, moderate (\<50%) improvement in 16%, and no improvement in 7% of patients. The authors note that most patients demonstrated rapid improvement within the first few weeks of treatment. Serum creatinine levels rose \>30% from baseline in 9.6% of patients, and hypertension developed in 15.1% of patients. Other side effects reported included paresthesias, hypertrichosis, headaches, fatigue, nausea, gingival hyperplasia, muscle cramps, folliculitis, and tremors. Upon discontinuation of cyclosporine, 45% of the patients experienced remission of their atopic dermatitis for at least 3 months, and 55% experienced relapse. Of note, 8% of patients who relapsed developed rebound disease that was more severe than baseline ([@b6-ppa-2-387]).

A prospective, randomized trial of 40 British children with atopic dermatitis compared the efficacy, safety, tolerability and quality of life of short-course and continuous treatment with cyclosporine. Children ages 2 to 16 years with severe atopic dermatitis were treated with either multiple short courses of 12 weeks each of cyclosporine 5 mg/kg or with continuous therapy for one year. Improvements in severity, area of involvement, irritability and sleep disturbance were statistically significantly in both groups from baseline to weeks 8, 12, and month 12. Although no significantly differences were seen between the groups at any particular time point, improvements fluctuated in the short course arm as a result of medication tapering and cessation. No patients showed clinically significantly changes in serum creatinine or blood pressure, and tolerability was considered good or very good in at least 80% of the patients. Although the mean cumulative dose of cyclosporine was greater in continuous arm than in the short-course arm (1068 and 836 mg/kg, respectively), the patients in the continuous arm demonstrated more consistent disease control ([@b4-ppa-2-387]).

Methotrexate
============

Methotrexate is a folic acid antagonist that is approved for the treatment of psoriasis, rheumatoid arthritis, and mycosis fungoides ([@b22-ppa-2-387]). Randomized controlled trials are lacking, but several small trials reported clinical improvement of moderate to severe atopic dermatitis in patients treated with methotraxate. A prospective trial of 12 patients evaluated the use of methotrexate for the treatment of moderate to severe atopic dermatitis. The average improvement in disease activity was 50% from baseline, and there were significantly improvements in quality of life, affected body surface area, and loss of sleep and itch scores ([@b21-ppa-2-387]). Although the use of methotrexate in atopic dermatitis is off label, its anti-inflammatory effects make it a useful second-line agent for the treatment of atopic dermatitis. Side effects include nausea and elevated liver enzymes, and patients occasionally develop pancytopenia or hepatic or pulmonary toxicity ([@b3-ppa-2-387]; [@b21-ppa-2-387]; [@b22-ppa-2-387]). Patients should be monitored closely when therapy is intiated, with complete blood count, liver enzymes, and creatinine levels 1 to 2 weeks after initiation of therapy and after any changes in dosing. Once long-term dosing levels have been established, repeat testing should be obtained every 3 to 4 months ([@b22-ppa-2-387]).

Azathioprine
============

Azathioprine was initially developed for the prevention of graft rejection in organ transplant patients. Additionally, azathiaprine's immunosuppressive properties make it a useful treatment for a number of diseases, including systemic lupus erythematosis, dermatomyositis, pemphigus vulgaris, and atopic dermatitis ([@b13-ppa-2-387]). Azathioprine is converted into 6-mercaptopurine, a purine analog that produces metabolites that incorporate into DNA. Although data on the use of azathioprine for atopic dermatitis are limited, there are several studies that support its use as a second-line treatment for severe, refractory disease. A review of 8 studies involving a total of 128 adult and pediatric patients treated with azathioprine documented overall improvement in atopic dermatitis symptoms in 7 of the 8 studies ([@b13-ppa-2-387]). In addition, a double-blind, randomized, placebo-controlled crossover study evaluated the safety and efficacy of azathioprine 2.5 mg/kg/day for 12 weeks in adult patients with severe atopic dermatitis. Subjects were evaluated using the SASSAD (Six Area Six Sign Atopic Dermatitis) sign score and demonstrated 26% reduction during azathioprine treatment, but only a 3% reduction with placebo. Pruritus, sleep disturbance, and disruption of work/daytime activity showed significantly improvements during azathioprine treatment but not with placebo treatment. While receiving azathioprine treatment, 14 subjects reported gastrointestinal side effects, 8 demonstrated abnormalities in their liver enzymes, and 2 became leukopenic ([@b1-ppa-2-387]).

The most common serious side effects of azathioprine are dose-dependant hepatotoxicity and myelotoxicity. Myelotoxicity has been shown to be related to activity of thiopurine methyltransferase (TPMT), an enzyme necessary for the metabolism of azathioprine. Approximately 10% of the population are heterozygous at the TPMT locus and demonstrate intermediate TPMT activity, putting them at increased risk for myelosupression when treated with azathoprine. Homozygous deficiency of TPMT is found in 0.33% of the population, and these individuals are likely to show profound myelosuppression when treated with azathioprine ([@b13-ppa-2-387]). A double-blind, placebo-controlled trial evaluated the safety and efficacy of azathioprine dosed by TPMT activity in moderate to severe atopic dermatitis. Patients with normal TPMT activity received 2.5 mg/kg/day, while those with heterozygous range TPMT activity received 1 mg/kg.day. At week 12, there was a 37% improvement in mean disease activity in the azathioprine group compared with 20% in the placebo group. Although response to the drug varied widely among participants, subjects with heterozygous TPMT activity responded to the medication in similar proportions to the participants with normal TPMT activity, and did not develop myelotoxicity ([@b12-ppa-2-387]).

Concerns also exist that long-term use of this medication may increase the risk of certain malignancies. These concerns stem from the increased rate of squamous cell skin cancers and non-Hodgkin's lymphoma in organ transplant patients who have received long-term immunosuppressive therapy that included azathioprine. However, studies of patients taking short- or medium-term courses of azathioprine do not demonstrate this increased risk of carcinogenicity ([@b13-ppa-2-387]).

Mycophenolate mofetil
=====================

Mycophenolate mofetil (MMF) has been used recently in the treatment of adult and pediatric patients with moderate to severe refractory atopic dermatitis. Although randomized controlled trials have not yet been done, several studies have demonstrated symptom improvement in patients treated with this drug ([@b5-ppa-2-387]; [@b15-ppa-2-387]).

MMF is a selective reversible inhibitor of inosine monophosphate dehydrogenase, an enzyme necessary for the de novo synthesis of purines. Lymphocytes lack the salvage pathway present in other inflammatory cell types, and are therefore dependent on the de novo synthesis pathway. Inosine monophosphate dehydrogenase inhibition results in selective suppression of lymphocytes.

A retrospective chart review examined 20 adult patients with moderate to severe atopic dermatitis treated with mycophenolate mofetil at starting doses of 500 mg to 1 g twice daily. Seventeen of the 20 patients showed improvement in disease severity after 2 to 4 weeks and were maintained on treatment. Ten patients eventually achieved complete clearance of atopic dermatitis and were tapered off of MMF. Although MMF was generally well tolerated, side effects included mild headaches, gastrointestinal complaints and fatigue. Four patients developed herpes zoster, 1 developed herpes simplex, and 2 developed cutaneous infections with *Staphylococcus aureus* ([@b15-ppa-2-387]).

A retrospective study of 14 pediatric patients with severe atopic dermatitis demonstrated that MMF was both a safe and effective treatment option. Over half of the patients achieved complete or almost complete clearance, and only one failed to respond. The authors initiated dosing at 40 to 50 mg/kg daily in younger children and 30 to 40 mg/kg daily in adolescents. They noted that initial responses typically occurred within 2 months, with maximal effect attained after 2 to 3 months. They reported no infectious complications in their cohort ([@b5-ppa-2-387]).

IFN-γ
=====

Interferon gamma (IFN-γ) is a cytokine that exerts anti-inflammatory effects by inhibiting IgE synthesis and T cell proliferation ([@b11-ppa-2-387]). Treatment with IFN-γ has been shown to decrease blood eosinophil counts in patients with atopic dermatitis, and has been shown to improve atopic dermatitis symptoms in patients with severe disease ([@b7-ppa-2-387]). A controlled trial of 51 patients with severe, recalcitrant atopic dermatitis compared low-dose (0.5 × 10^6^ IU/m^2^) IFN-γ, high-dose (1.5 × 10^6^ IU/m^2^) IFN-γ, and placebo treatment 3 times per week over 12 weeks. Both groups treated with IFN-γ showed significantly reduction in disease severity. The high-dose group showed more rapid and effective treatment outcome at week 6, but improvement in both groups remained stable after week 8, leading the authors to suggest a regimen of initial high-dose therapy, followed by maintenance therapy at the lower dosage. Potential side effects associated with IFN-γ therapy include transient fever, myalgias, respiratory difficulties, and elevation of LDH or transaminases ([@b7-ppa-2-387]).

Conclusion
==========

Atopic dermatitis is a chronic inflammatory skin disease that affects both children and adults and causes significantly physical, psychological, social, and emotional stress for patients and their families. Although topical steroids have been the first-line treatment for atopic dermatitis for the past half century, advances in our understanding of disease pathogenesis and new developments in immunosuppressive medications have expanded the therapeutic options available to treat this disease. The topical medications available for atopic dermatitis have expanded to incorporate new vehicle technologies as well as steroid-sparing topical calcineurin inhibitors. The use of systemic immunosuppressants, including cyclosporine, methotrexate, azathioprine, mycophenilate mofetil, and IFN-γ has become more common, particularly for severe, refractory disease.
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